Breast Cancer | Clinical

May 13, 2021

Patients with high-risk, early-stage triple-negative breast cancer in the phase 3 KEYNOTE-522 trial of pembrolizumab plus chemotherapy after surgery demonstrated statistically significant event-free survival.

May 11, 2021

In an interview with Targeted Oncology, Komal Jhaveri, MD, FACP, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses HER2-positive metastatic breast cancer innovations, treatments, and upcoming studies.

May 03, 2021

Erika P. Hamilton, MD, discusses the data leading up to the Next MONARCH 1 study of abemaciclib plus tamoxifen or abemaciclib alone with metastatic breast cancer.

April 30, 2021

Here is a look back at the FDA happenings from the month of April 2021.

April 29, 2021

The experts describe the SOPHIA study of margetuximab in HER2+ advanced breast cancer.

April 29, 2021

Experts have a detailed conversation on the NALA trial of neratinib and capecitabine for HER2+ metastatic breast cancer.

April 29, 2021

Presentation and considerations for relapsed HER2+ metastatic breast cancer with progressing brain metastases.

April 27, 2021

The FDA's Oncologic Drugs Advisory Committee voted 7 to 2 in favor of the continued approval of atezolizumab in combination with nab-paclitaxel for the treatment of patients with advanced or metastatic triple-negative breast cancer whose tumors are positive for PD-L1 expression.

April 16, 2021

As long-awaited results from pivotal trials are revealed during major medical conferences, community oncologists in the clinic look forward to the resulting approvals with much anticipation.

April 13, 2021

For patients with metastatic breast cancer, research suggests that utilizing a multi-omics approach to personalized therapy that incorporates information about actionable oncogenic drivers with critical biological data may be feasible and better than DNA sequencing alone.